← SynDRA
FEDRATINIB
SynDRA canonical compound SYN0024886 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | JAK2 |
|---|
| Mechanism of action | FLT3 inhibitor |
|---|
| Indication | myelofibrosis |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- JAK2
- FLT3
- JAK1
- JAK3
- TYK2
- BRD4
- RET
- PDGFRB
- PDGFRA
- PAK6
- PAK5
- PAK4
Mechanisms of action (all sources)
- JAK inhibitor
- FLT3 INHIBITOR
- Tyrosine-protein kinase receptor FLT3 inhibitor
- JAK2 INHIBITOR
- Tyrosine-protein kinase JAK2 inhibitor
- BET bromodomain inhibitor
- JAK1 INHIBITOR
- JAK3 INHIBITOR
- TYK2 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- YJ005
- ADRA2C
- DLK1
- CHRM3
- DRD3
- CHRM1
- PDE4D
- GHSR
- SCN5A
- NR1I2
- SLC6A3
- SLC6A4
- HRH3
- HTR2A
- SLC6A2
- KCNH2
- ADORA3
- ADORA1
- ADORA2A
- MAT2A
- MAPK14
- PAICS
- PAK3
- PCYT1A
- PDE3A
- MAPK3
- PDPK1
- PDXK
- PEBP1
- PFKP
- MAPK12
- MAPK13
- OPRM1
- PGR
- PGRMC1
- PIK3C2B
- MAPK11
- PIK3C2G
- PIK3CB
- PIK3CD
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- GAMT
- GNMT
- HLA-B
- HLAB
- HNMT
- IFNB1
- IFNG
- KSYK
- NNMT
- NSD2
- PARP1
- PNMT
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- INREBIC
- Inrebic
- fedratinib hydrochloride
- SAR302503
- SAR-302503
- TG101348
- TG-101348
- FEDR
- inrebic
- TG.101348
- TG 101348
- SAR 302503
- Fedratinib (SAR302503, TG101348)
- TG101348 (SAR302503)
- CHEMBL1287853
- 6L1XP550I6
- 936091-26-8 (free base)
- Fedratinib [USAN]
- Fedratinib [USAN:INN]
- UNII-6L1XP550I6
- C27H36N6O3S
- 2TA
- FEDRATINIB [MI]
- FEDRATINIB [INN]
- Fedratinib (USAN/INN)
- TG101348(Fedratinib)
- FEDRATINIB [WHO-DD]
- Fedratinib (TG101348)
- MLS006011155
- SCHEMBL263741
- GTPL5716
- CHEBI:91408
- DTXSID90239483
- EX-A170
- HMS3295I03
- HMS3656L19
- HMS3744G17
- HMS3868L03
Reported adverse events
- Wernicke's encephalopathy
- Amylase increased
- Aspartate aminotransferase increased
- Blood creatinine increased
- Bone pain
- Dizziness
- Dysuria
- Encephalopathy
- Fatigue
- Headache
- Lipase increased
- Muscle spasms
Look up FEDRATINIB in the interactive SynDRA portal →